Botwood Nicholas A.J. Sells Shares of SNDX $SNDX
Key Points
- Botwood Nicholas A.J. sold 31,235 shares of Syndax Pharmaceuticals, Inc. ($SNDX) worth $566,603.
- $SNDX last traded around $18.25.
Botwood Nicholas A.J., Head of R&D, CMO at Syndax Pharmaceuticals, Inc. ($SNDX), sold 31,235 shares at an average price of $18.14, for a total transaction of $566,603. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Syndax Pharmaceuticals, Inc. ($SNDX) Stock
Syndax Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.